SHAREHOLDER ALERT: The Pomerantz Law Firm announces the filing of a class action lawsuit against GoodRx Holdings, Inc.

NEW YORK , May 30, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX). Investors are urged to contact Danielle Peyton at (email protected) or 646-581-9980 (or 888.4-POMLAW), toll-free, extension 7980. For inquiries by email, you will be asked to provide your mailing address, telephone number and the number of shares purchased.

The class action lawsuit concerns whether GoodRx and certain of its officers and/or directors engaged in securities transactions Fraud or other unlawful business practices.

You have until 21 June 2024to ask the Court to appoint you as lead plaintiff for the class if you are a shareholder who purchased or otherwise acquired GoodRx securities during the Class Period. A copy of the complaint is available atT www.pomerantzlaw.com.

(Click here for information on joining the class action lawsuit.)

At May 9, 2022GoodRx disclosed that in late Q1 2022, “a grocery chain took action that impacted the acceptance of rebates from most PBMs (pharmacy benefit managers) for a subset of drugs” and that this “impacted the acceptance of many PBM rebates for certain drugs in this grocer’s stores.” GoodRx further acknowledged that this disruption “is estimated to have a revenue impact of approximately 30 million US dollars” in the second quarter of 2022 – which led the company to issue a disappointing revenue forecast for the second quarter of 2022 of only approximately 190 million US dollars. In the accompanying investor conference call on the same day, GoodRx’s Co-Chief Executive Officer Trevor Bezdek admitted that the use of GoodRx rebates at the “grocery chain” accounted for nearly 25% of GoodRx’s prescription drug revenue. While the company declined to name the grocer, analysts and media quickly realized that the unnamed grocery chain was Kroger.

Following this news, GoodRx’s share price fell 2,78 € per share or more than 25% to close at 7,97 € per share on 10th of May2022.

Then on 8 November 2022GoodRx provided further information on the severity of the revenue impact from the disruption at Kroger, estimating that the “impact of the grocer issue on third quarter (prescription drug sales) was approximately 40 million US dollars” and that the company “has a combined 45 million US dollars To 50 million US dollars Estimated impact on prescription drug transaction revenue” for the fourth quarter of 2022. GoodRx further confirmed that the company is committed to entering into contractual relationships with pharmacies to prevent similar disruptions in the future.

Following this news, GoodRx’s share price fell further 1,18 € per share, or more than 22%, and closed at $4.06 per share on 9 November 2022.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of victims of securities class action litigation. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.